Veritas Genetic participates in a groundbreaking study highlighting the importance of polygenic risk scores in the clinical management of breast cancer patients

Veritas Genetics United Kingdom United States of America France Germany Spain

The study, conducted in collaboration with the Department of Biomedicine and Prevention at the University of Rome Tor Vergata and Tor Vergata University Hospital, underscores the relevance of polygenic risk scores (PRS) in risk stratification for patients with a genetic predisposition to breast cancer.View original content:https://www.prnewswire.co.uk/news-releases/veritas-genetic-participates-in-a-groundbreaking-study-highlighting-the-importance-of-polygenic-risk-scores-in-the-clinical-management-of-breast-cancer-patients-302265829.html